Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference

Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2(V617F) mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Andrew, Liu, James, Pu, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182587/
https://www.ncbi.nlm.nih.gov/pubmed/37173704
http://dx.doi.org/10.1186/s13045-023-01446-0
_version_ 1785041786152943616
author Wang, Andrew
Liu, James
Pu, Jeffrey J.
author_facet Wang, Andrew
Liu, James
Pu, Jeffrey J.
author_sort Wang, Andrew
collection PubMed
description Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2(V617F) mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting.
format Online
Article
Text
id pubmed-10182587
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101825872023-05-14 Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference Wang, Andrew Liu, James Pu, Jeffrey J. J Hematol Oncol Correspondence Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2(V617F) mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting. BioMed Central 2023-05-12 /pmc/articles/PMC10182587/ /pubmed/37173704 http://dx.doi.org/10.1186/s13045-023-01446-0 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Wang, Andrew
Liu, James
Pu, Jeffrey J.
Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
title Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
title_full Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
title_fullStr Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
title_full_unstemmed Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
title_short Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
title_sort novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ash annual conference
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182587/
https://www.ncbi.nlm.nih.gov/pubmed/37173704
http://dx.doi.org/10.1186/s13045-023-01446-0
work_keys_str_mv AT wangandrew novelagentsandevolvingstrategiesinmyelofibrotiveneoplasmanupdatefrom2022ashannualconference
AT liujames novelagentsandevolvingstrategiesinmyelofibrotiveneoplasmanupdatefrom2022ashannualconference
AT pujeffreyj novelagentsandevolvingstrategiesinmyelofibrotiveneoplasmanupdatefrom2022ashannualconference

Ejemplares similares